American Glaucoma Society Meeting
American Glaucoma Society Meeting
March 05, 2018
1 min read

Early follow-up after Xen implantation needed

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

NEW YORK — Nearly 80% of patients who received a Xen gel stent with IOP-lowering topical medication after surgery experienced an IOP of less than 18 mm Hg, but early interventions were needed in 20% of patients, according to a speaker here.

“Careful follow-up is necessary at 1 month as most failures, complications and need for medications clustered around this time,” Ramesh Ayyala, MD, FRCS, FRCOphth, said at the American Glaucoma Society annual meeting.

In a longitudinal retrospective study, 211 eyes underwent Xen (Allergan) implantation. At baseline, the mean IOP for the cohort was 22 mm Hg. Qualified success was defined as an IOP of 6 mm Hg to 18 mm Hg with IOP-lowering topical medications, while absolute success was defined as an IOP of 6 mm Hg to 18 mm Hg without additional topical medications, Ayyala said.

At 6 months postoperative, less than one-fourth of eyes (22%) were deemed to be absolute successes. Additionally, Ayyala said interventions were required in nearly 20% of all eyes, with most needling and injection interventions needed in the first postoperative month. – by Robert Linnehan



Ayyala R, et al. Xen gel stent early results: Safety and efficacy in the short term. Presented at: American Glaucoma Society annual meeting; Feb. 28 to March 4, 2018; New York.


Disclosure: Ayyala reports no relevant financial disclosures.